La Protein as a Novel Regulator of Osteoclastogenesis
Summary:
NICHD seeks co-development partners and/or licensees for the further development of methods to target the La protein for the regulation of osteoclast fusion and osteoclastogenesis.
Nandrolone 17 Beta-Carbonates
Summary:
Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development are highly motivated in seeking licensing and/or collaboration partners for the development and use of androgenic compounds as contraceptives and/or hormonal therapeutics.
Therapeutics Against Pathogenic Coronaviruses
Summary:
Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development are highly motivated in seeking research co-development partners and/or licensees to further develop and commercialize PIKfyve phosphatidyl linositol kinase inhibitors for the treatment of pathogenic coronaviruses. An ideal partner would enter into both a Cooperative Research and Development Agreement (CRADA) and an exclusive license agreement towards commercialization of this technology.
Enhanced Antigen Reactivity of Immune Cells Expressing a Mutant Non-Signaling CD3 Zeta Chain
Summary:
Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development are highly motivated in seeking licensing and/or collaboration partners to develop therapeutic cell populations arising out of these technologies. An ideal partner would enter into both a Cooperative Research and Development Agreement (CRADA) and an exclusive license agreement towards commercialization of one or more therapies to treat various oncologies.
Camel VHH Nanobodies Bind the S2 Subunit of SARS-CoV-2 and Broadly Neutralize Variants including Omicron
Summary:
The NCI seeks research co-development partners and/or licensees to further develop this nanobody as a possible treatment of COVID-19 infections.
An Anti-Viral Polypeptide: Griffithsin
Summary:
Researchers at the NCI seek licensing and/or co-development research collaborations for anti-viral Griffithsin (GRFT) proteins.
Single Domain Antibodies (Nanobodies) Targeting SARS-CoV-2 for treating COVID-19
Summary:
The NCI seeks licensing and/or co-development research collaborations for SARS-CoV-2 targeting nanobodies.
T-cell Phenotypes Associated with Clinical Response to Adoptive Immunotherapy
Summary:
The NCI seeks applications from parties interested in co-developing and/or licensing a method to develop improved cancer immunotherapies.
HLA-A*01:01 Restricted Human T Cell Receptor Recognizing the NRAS Q61K Hotspot Mutation
Summary:
The NCI is seeking research co-development and/or licensees for the HLA-A*01:01 restricted human T-cell receptor recognizing the NRAS Q61K hotspot mutation.
Small Molecule Ephrin (Eph) Tyrosine Kinase Inhibitors for the Treatment of Colorectal Cancer and Other Eph Growth-dependent Solid Tumors
Description of Technology:
Advanced colorectal carcinoma is currently incurable, and new therapies are urgently needed. Ephrin (Eph) receptors are a clinically relevant class of receptor tyrosine kinases. Related signaling pathways are associated with oncogenesis of a number of cancers. NCI investigators found that phosphotyrosine-dependent Eph receptor signaling sustains colorectal carcinoma cell survival, thereby uncovering a survival pathway active in colorectal carcinoma cells.